Loreto Carmona to Biological Products
This is a "connection" page, showing publications Loreto Carmona has written about Biological Products.
Connection Strength
0.635
-
Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis. Reumatol Clin (Engl Ed). 2020 Sep - Oct; 16(5 Pt 2):378-385.
Score: 0.260
-
Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. Reumatol Clin (Engl Ed). 2020 Mar - Apr; 16(2 Pt 1):116-119.
Score: 0.063
-
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. Rheumatol Int. 2018 09; 38(9):1735-1740.
Score: 0.063
-
Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int. 2018 Jun; 38(6):975-983.
Score: 0.062
-
Perceptions of patients with rheumatic diseases treated with subcutaneous biologicals on their level of information: RHEU-LIFE Survey. Reumatol Clin (Engl Ed). 2019 Nov - Dec; 15(6):343-349.
Score: 0.061
-
Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol. 2017 May-Jun; 35(3):423-430.
Score: 0.057
-
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015 Jan; 67(1):117-27.
Score: 0.050
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.018